NCT05265052 2026-03-11
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
3D Medicines
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT07001709 2025-06-03
ENABLE
Deventer Ziekenhuis
Phase 4 Recruiting
NCT06897917 2025-03-27
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Henan Cancer Hospital
Phase 4 Not yet recruiting
NCT04808531 2022-04-12
NanaBisâ„¢ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers
Medlab Clinical
Phase 3 Unknown
NCT03176121 2020-03-18
STOP Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
Phase 4 Completed
NCT03176199 2020-03-18
A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain
Taiwan Mundipharma Pharmaceuticals Ltd.
Phase 4 Completed
NCT02660229 2018-11-19
SWITCH
Mundipharma Korea Ltd
Phase 4 Completed
NCT01675622 2018-05-21
Immediate-Release Oxycodone Capsules Study in Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01313780 2017-12-22
TOP
Mundipharma Korea Ltd
Phase 4 Completed
NCT01809106 2015-12-24
CERP
Mario Negri Institute for Pharmacological Research
Phase 4 Completed
NCT00916890 2014-01-09
Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 4 Suspended